28715-26-6

Basic information

• Product Name: 4,7-dimethylbenzofuran
• Synonyms: 4,7-dimethylbenzofuran
• CAS NO: 28715-26-6
• Molecular Formula: C₁₀H₁₀O
• Molecular Weight: 146.1858
• EINECS: 249-184-6
• Mol File: 28715-26-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 216°C (estimate)
• Flash Point: 86.4°C
• Appearance: /
• Density: 1.0410
• Vapor Pressure: 0.188mmHg at 25°C
• Refractive Index: 1.5490 (estimate)
• CAS DataBase Reference: 4,7-dimethylbenzofuran(CAS DataBase Reference)
• NIST Chemistry Reference: 4,7-dimethylbenzofuran(28715-26-6)
• EPA Substance Registry System: 4,7-dimethylbenzofuran(28715-26-6)

Safety Data

• Hazardous Substances Data: 28715-26-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H10O/c1-7-3-4-8(2)10-9(7)5-6-11-10/h3-6H,1-2H3

Upstream product

• 289891-92-5 2,2-diethyl-2,4-dimethylphenyl ether 
• 95-87-4 2,5-Dimethylphenol 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 110-00-9 furan 
• 625-86-5 2,5-dimethylfuran 

Downstream Products

• 196520-11-3 methyl 4-[4-(4,7-dimethylbenzofuran-2-yl)-4-oxo-butanoyl]benzoate 
• 196520-04-4 methyl 4-[5-(4,7-dimethylbenzofuran-2-yl)pyrrol-2-yl]benzoate 

Relevant articles and documents

Characteristic flavor formation of thermally processed N-(1-deoxy-α-D-ribulos-1-yl)-glycine: Decisive role of additional amino acids and promotional effect of glyoxal

The role of amino acids and α-dicarbonyls in the flavor formation of Amadori rearrangement product (ARP) during thermal processing was investigated. Comparisons of the volatile compounds and their concentrations when N-(1-deoxy-α-D-ribulos-1-yl)-glycine r

Direct Dimesitylborylation of Benzofuran Derivatives by an Iridium-Catalyzed C?H Activation with Silyldimesitylborane

Direct dimesitylborylation of benzofuran derivatives by a C?H activation catalyzed by an iridium(I)/N-heterocyclic carbene (NHC) complex in the presence of Ph2MeSi-BMes2 afforded the corresponding dimesitylborylation products in good to high yield with excellent regioselectivity. This method provides a straightforward route to donor–(π-spacer)–acceptor systems with intriguing solvatochromic luminescence properties.

Retinoic acid agonists as preventive and therapeutic agents for nephritis

The present invention provides a therapeutic or prophylactic agent as a substitute for conventional steroids or immunosuppressive agents to treat or prevent systemic erythematosus, glomerulonephritis, lupus nephritis, idiopathic thrombocytopenic purpura or autoimmune anemia. The agent comprises a retinoic acid receptor agonist, specifically a retinoic acid receptor subtype α (RARα) agonist, including for example: (1) carboxylic acid compounds having condensed rings represented by the following formula: ?(wherein the rings L and M are condensed, are the same as or different from each other, and represent an aromatic hydrocarbon which may have a substituent group or a heterocycle which may have a substituent group; the rings A and B are independent of each other and represent an aromatic hydrocarbon ring or heterocycle which may have a substituent group; and D represents a carboxyl group which may have a protective group), (2) 4-{[(3,5-bistrimethylsilylphenyl)carbonyl]amino}benzoic acid, 4-{2-[5-(3-methoxymethyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-yl)pyrrolyl]}benzoic acid, etc.